Investment in Thermo Fisher Scientific (TMO) shares has been fluctuating, with several investment firms buying and others selling. Increased holding by companies like Morgan Stanley, DAVENPORT & Co LLC, and Andrew Hill Investment Advisors Inc. contrasts reduced stakes from firms such as Carnegie Investment Counsel and Coho Partners Ltd. Thermo Fisher's favorable Q3 results and improved guidance have been notable market catalysts. A 12% upside and potential expansion with Alzheimer's bioprocessing tools and registry intake have generated investor interest. Citigroup has upgraded TMO, with Goldman Sachs also providing a buy recommendation. Thermo Fisher has declared quarterly dividends and announced a new $5 billion share repurchase program. Additionally, the company outperformed Q3 expectations with a 5% revenue increase. Intrinsic value estimation of Thermo Fisher stocks suggests further market interest. Key institutional and investment advancements include TMO's acquisition of Clario Holdings for $8.88 Billion and a promising partnership with OpenAI for drug development innovation. Notably, Thermo Fisher launched a Molecular Assay for rapid beverage quality testing, the first in the industry, and a new Alzheimer registry to advance neurodegenerative care.
Thermo Fisher Scientific TMO News Analytics from Thu, 31 Jul 2025 07:00:00 GMT to Sat, 27 Dec 2025 10:57:25 GMT - Rating 7 - Innovation 6 - Information 8 - Rumor -4
